Q2 2025
Released Nov 7, 2024, before the open
10-Q filed Nov 7, 2024, 38 days after period end · 0001764013-24-000184
Q2 2025 · 10-Q
Revenue—
Net Income-$109.12M-$109.12M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.74-$0.74 N/M vs Q2 2024N/M vs Q1 2025
Operating Cash Flowderived-$88,647,000N/M
Free Cash Flowderived-$88,843,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$109.12M | -$58.66M | -$47.93M | -$37.70M |
| EPS Diluted | -$0.74 | -$0.45 | -$0.41 | -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR